Xylem raises FY23 adjusted EPS view to $3.50-$3.70 from $3.15-$3.35

FY23 consensus $3.18. Xylem now expects full-year 2023 revenue of approximately $7.2B, consensus $7.02B, up approximately 30% on a reported basis and up 9 to 10% on an organic basis. This represents an increase from the company’s previous full-year guidance of 8 to 9% on an organic and reported basis. Full-year 2023 adjusted EBITDA margin is expected to be approximately 18 percent, lifted from the previous range of 17.5 to 18.0 percent.